The HEBP2 Knockout NCI-H1975 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of NCI-H1975 lung adenocarcinoma cells in which HEBP2 has been disrupted to establish a loss-of-function model. As a polyclonal knockout product, it offers a heterogeneous pool of edited cells, facilitating functional analyses without the limitations of single-cell cloning. This cell model is designed for studying the role of heme-binding protein 2 in oncogenic and stress signaling contexts.
The NCI-H1975 cell line is an epithelial lung adenocarcinoma model harboring EGFR mutations (L858R/T790M), representing a clinically relevant subtype of non-small cell lung cancer (NSCLC). This cell line serves as a standard platform for investigating EGFR-driven oncogenesis and acquired resistance to tyrosine kinase inhibitors, including osimertinib. Its defined genetic background enables targeted studies of signaling networks and drug sensitivity mechanisms.
HEBP2 encodes a heme-binding protein that buffers intracellular free heme and modulates oxidative stress. HEBP2 is transcriptionally regulated by heme, NFE2L2 (NRF2), and HIF1A, and it functionally interacts with heme oxygenase-1 (HMOX1) to influence heme degradation. Through these interactions, HEBP2 impacts the expression of NQO1, BCL2 family members (e.g., BCL2, BAX), and caspase-3, thereby linking heme metabolism to ROS detoxification and apoptotic signaling. This positions HEBP2 as a molecular bridge between heme homeostasis and cell survival pathways.
In NCI-H1975 cells with EGFR mutations, HEBP2 knockout is anticipated to impair heme buffering, elevating free heme and reactive oxygen species, which may enhance apoptotic priming and alter chemosensitivity. This model provides a physiologically relevant system for dissecting the crosstalk between heme metabolism, oxidative stress responses, and EGFR signaling in lung adenocarcinoma. Consequently, it enables investigation of HEBP2 as a potential modifier of drug responses, particularly to osimertinib.
Researchers can employ this polyclonal knockout population to examine heme homeostasis and oxidative stress pathways via Western blotting, RT-qPCR, heme quantification, and ROS detection (e.g., DCFDA). Apoptosis assays (Annexin V/PI) and cell viability tests under heme treatment can assess stress-induced cell death. Additionally, drug sensitivity profiling with osimertinib supports the study of therapeutic resistance. These applications position the model as a versatile tool for validating HEBP2-related signaling and exploring novel NSCLC treatments. For further information, please contact Ascent Research.
